MANDI PARKS: Open Payments
NPI 1760966188 · SALEM, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$617 in 37 payments from 13 companies in 2025. Trend: 2023 $305 · 2024 $564 · 2025 $617
Food & beverage: $617
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 14 | $173 |
| ABBVIE INC. | 6 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $66 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Indivior Inc. | 2 | $41 |
| Braeburn Inc. | 2 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Grifols USA, LLC | 1 | $30 |
| Ardelyx, Inc. | 1 | $22 |
| Exact Sciences Corporation | 1 | $20 |
Products named: REPATHA, OTEZLA, CAPLYTA, MAVYRET, REXULTI, SUBLOCADE, VRAYLAR, BRIXADI.
Industry payments across MO — which companies pay providers there.
